Curanex Pharmaceuticals (CURX) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -89% return. The company has lost about $25 Mil in value over the last 5 days, with its current market capitalization at about $28 Mil. The stock remains 63.9% above its value at the end of 2024. This compares with year-to-date returns of 13.2% for the S&P 500.
CURX no company description provided to compress. Please provide the description for assistance.
Comparing CURX Stock Returns With The S&P 500
The following table summarizes the return for CURX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CURX | S&P 500 |
|---|---|---|
| 1D | -4.8% | -0.6% |
| 5D (Current Streak) | -89.1% | 0.8% |
| 1M (21D) | 63.9% | 2.9% |
| 3M (63D) | 63.9% | 9.3% |
| YTD 2025 | 63.9% | 13.2% |
| 2024 | 0.0% | 23.3% |
| 2023 | 0.0% | 24.2% |
| 2022 | 0.0% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 57 S&P constituents with 3 days or more of consecutive gains and 62 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 24 | 38 |
| 4D | 12 | 13 |
| 5D | 15 | 4 |
| 6D | 4 | 3 |
| 7D or more | 2 | 4 |
| Total >=3 D | 57 | 62 |
Key Financials for Curanex Pharmaceuticals (CURX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-19,298 | $-0.3 Mil |
| Net Income | $-19,198 | $-0.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-0.1 Mil | $-57,658 |
| Net Income | $-0.1 Mil | $-60,346 |
The losing streak CURX stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Disclaimer: The story “CURX Stock Down -89% after 5-Day Loss Streak” first appeared on Trefis and is syndicated via Digpu & NewsTex.